Corticosteroid-Associated Adverse Events in Chronic Spontaneous Urticaria: A US Claims Data Study
Open Access
- 5 May 2026
- journal article
- research article
- Published by Springer Nature in Dermatology and Therapy
- Vol. 16 (8) , 1-14
Abstract
Introduction Chronic spontaneous urticaria (CSU) is a skin disorder for which short-course systemic corticosteroids are recommended only as rescue medication during acute exacerbations. Here, we describe real-world corticosteroid use, adverse events (AEs) occurring post-corticosteroid initiation, and health care resource utilization (HCRU) of patients with CSU in the USA. Methods This retrospective cohort study used data from the US HealthVerity claims database of adults with diagnosed CSU (January 2016–March 2023). Only prescription and non-antihistamine claims were included in the analysis of treatment patterns. In the AE and HCRU analyses, patients were stratified into five cohorts on the basis of total days of systemic corticosteroid supply as a proxy for duration of use: ≤ 31 days, > 31 to ≤ 60 days, > 60 days, ≥ 90 days (subcohort of > 60 days), and non-corticosteroid users. Results Of 200,298 patients, corticosteroids were the most prescribed treatment (78.3% all; 68.2% systemic) following CSU diagnosis, excluding over-the-counter medication and antihistamines. The ten most common AEs occurring after systemic corticosteroid initiation (hypertension, lipid disorders, anxiety, obesity, fatigue, depression, diabetes, insomnia, cataracts, and gastritis) occurred in higher proportions of all corticosteroid user types versus non-users. The proportion of patients experiencing AEs generally increased with longer duration of corticosteroid use. More frequent HCRU was generally observed after the first systemic corticosteroid prescription and with increasing duration of corticosteroid use. Conclusions Patients with CSU who were prescribed corticosteroids reported a higher proportion of AEs and more frequent HCRU than those who were not. These trends in AEs and HCRU were more prominent with increasing duration of corticosteroid use.Keywords
Funding Information
- Novartis Pharmaceuticals Corporation
This publication has 28 references indexed in Scilit:
- Clinical burden, treatment, and disease control in patients with chronic spontaneous urticariaAnnals of Allergy, Asthma & Immunology, 2024
- Topical corticosteroids for hives and itch (urticaria): Systematic review and Bayesian meta-analysis of randomized trialsAnnals of Allergy, Asthma & Immunology, 2024
- Efficacy and Safety of Systemic Corticosteroids for Urticaria: A Systematic Review and Meta-Analysis of Randomized Clinical TrialsThe Journal of Allergy and Clinical Immunology: In Practice, 2024
- 44231 Variability in Treatment Patterns across Specialties in the Management of Chronic Spontaneous Urticaria (CSU): A Real-World Survey in the USJournal of the American Academy of Dermatology, 2023
- Prevalence estimates for chronic urticaria in the United States: A sex- and age-adjusted population analysisJournal of the American Academy of Dermatology, 2019
- Cyclosporine for Chronic Spontaneous Urticaria: A Meta-Analysis and Systematic ReviewThe Journal of Allergy and Clinical Immunology: In Practice, 2018
- Effect of chronic urticaria on US patients: analysis of the National Health and Wellness SurveyAnnals of Allergy, Asthma & Immunology, 2015
- Resource Use and Costs in an Insured Population of Patients with Chronic Idiopathic/Spontaneous UrticariaAmerican Journal of Clinical Dermatology, 2015
- Validation of an ICD-9–based claims algorithm for identifying patients with chronic idiopathic/spontaneous urticariaAnnals of Allergy, Asthma & Immunology, 2015
- Cost, utilization, and patterns of medication use associated with chronic idiopathic urticariaAnnals of Allergy, Asthma & Immunology, 2012